[Treatment of the diabetic retinopathy with doxium-clofibrate (author's transl)].
28 patients with non proliferating exudative diabetic retinopathy were treated with 750 mg Doxium and 1500 mg Clofibrate daily during 8.6 months on an average. Before beginning--in the middle of the period of observation--and after finishing the treatment, a retinal fluorescein angiography was performed. The waxy exudates decreased in 11 patients (39.29%) and increased in 8 patients (28.57%). In 9 patients (32.14%) no change of the amount of the hard exudates was observed. The treatment was almost only in those angiopathies successful, in which the fluorescein angiography showed a preponderance of the hyperpermeability over the obliterating process of retinal capillaries.
D000328:Adult; D000368:Aged; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002123:Calcium Dobesilate / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged
D001557:Benzenesulfonates; D002123:Calcium Dobesilate; D002994:Clofibrate
Die Behandlung der exsudativen diabetischen Retinopathie mit Doxium-Clofibrat